Edition:
HIGHLIGHTS
Donald Trump’s China policy
NEW
US-China relationsHong Kong economy
News
Hong KongChinaEconomyAsiaWorldSportThis Week in AsiaUS Elections
Business & Tech
BusinessTech
Opinion
Latest
Lifestyle
LifestylePeople & CultureStylePostMagK-popOutdoorCooking
More +
VideoTalking PostSCMP FilmsInfographicsPicturesPodcastsSCMP SeriesExplainedSCMP SpotlightNewslettersSpecial Reports
Topics
Donald Trump’s China policyUS-China relationsHong Kong’s Article 23 national security lawChina’s militaryChina's economic recoveryTrending in ChinaTaiwanChina’s Communist PartyUkraine warWellness
Focus
Greater Bay Area
We use cookies to tailor your experience and present relevant ads. By clicking “Accept”, you agree that cookies can be placed per our Privacy Policy
ACCEPT
Advertisement
avatar image
TOPIC

Biomedicine: Science

Related Topics:
Biomedicine: Companies
Biomedicine: Policy
Biomedicine: Science
Biomedicine: Industry Trends
Biomedicine: Geopolitics
Biomedicine: Science
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
Pfizer agreed to buy a 1.3 per cent equity stake in 3SBio for HK$785 million. Photo: Shutterstock
Biomedicine: Companies

Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity investment in 3SBio.

Biomedicine: Companies

Hong Kong firms eye Chinese medicine opportunities on the mainland: HKTDC

China manufacturing

China approving innovative drugs at record pace, shifting momentum from West

videocam
6
Biomedicine: Companies

As Hong Kong suicides rise, AI start-up targets ‘hidden’ depression

Existing government efforts are not sufficient to find ‘hidden patients’, such as those with mild symptoms, co-founder says.

videocam
AniTech founder Eddie Ma (left) and CEO Candy Lau, at City University of Hong Kong on July 10, 2025. Photo: Jonathan Wong
Biomedicine: Companies

CUHK start-ups eye silver economy’s need for ‘wearable robotics’

Start-ups seek to enter the growing markets for elderly care and rehabilitation by selling their ‘wearable robotics’ technologies.

Biomedicine: Companies

Chinese biotech firms eye foreign pharma’s fat profits in weight loss drug market

Over 60 novel drug candidates are in late-stage clinical trials in China, and these will potentially compete directly with US drugmakers.

Advertisement
Advertisement
Advertisement
Artificial intelligence

Hong Kong’s IntelliGen AI takes on Google DeepMind in drug discovery

The start-up, which aims to raise tens of millions of US dollars in an angel funding round, hopes to compete globally, founder says.

IntelliGen AI, an artificial intelligence (AI) start-up founded in Hong Kong, is positioning itself as a competitor to Google DeepMind in the field of drug discovery, as the city increasingly seeks to bolster its AI capabilities.
Biomedicine: Companies

Explainer | Why dozens of Chinese firms are joining the weight loss drugs fray

In China, over 60 late-stage drugs are undergoing clinical trials, and may compete with those from incumbents Novo Nordisk and Eli Lilly.

Science

Mammals could regenerate tissue by turning on ‘genetic switch’: Chinese team

Scientists studying ability of mice to regenerate ear damage say therapies based on retinoic acid might work across various tissue types.

videocam
Biomedicine: Companies

China’s drug innovators bank on AI to hasten discovery to commercial success

A deal between Shenzhen-based XTalPi and US firm DoveTree shows Chinese biotech AI capabilities are gaining recognition.

videocam
Artificial intelligence assistant in a biotechnology experiment. Photo: Shutterstock Images
Health & Fitness

MingMed seeks Hong Kong listing to fund research and launch Botox alternative

Drug developer says it will set up an incubation centre in the Hong Kong Science and Technology Park in the third quarter.

MingMed CEO Zhang Yan. Photo: Handout
Hong Kong economy

Opinion | Hong Kong must reform its degree offerings to attract West’s brightest

Universities must evolve and burnish their offerings in the latest disciplines, from AI to cybersecurity, as US crackdowns send more to the East.

videocam
Artificial intelligence

Biotech firm touts new AI drug discovery amid third Hong Kong IPO attempt

Insilico Medicine said results of a clinical trial in China showed positive results in treating idiopathic pulmonary fibrosis.

Science

China boosts Southeast Asian populations overlooked in Human Genome Project

Before China took a role in the research, fewer than 200 indigenous genomes from MSEA existed in global databases, according to Nature paper.

videocam
Kunming Institute of Zoology is working to rectify the underrepresentation of mainland Southeast Asia populations in the Human Genome Project. Image: Shutterstock
Biomedicine: Companies

Chinese biotech firm Akeso sinks after US partner’s cancer-drug setback

FDA says a ‘statistically significant’ benefit on overall survival is required to approve the ivonescimab antibody.

Akeso’s clinical trials in China showed that ivonescimab allowed half of its patients to go 11.1 months without their cancer progressing. Photo: Shutterstock
Artificial intelligence

XPrize founder Diamandis projects hope for AI, biotech amid US-China tech war

The entrepreneur says biotech should be less contentious than AI, as a breakthrough in Beijing is just as usable in Boston.

videocam
Robotics

Hong Kong surgical robot start-up Cornerstone takes aim at da Vinci

Company aims to raise US$70 million to develop its systems, which it claims rival the market-leading da Vinci units at lower cost.

Advertisement
Advertisement
Advertisement
Biomedicine: Companies

Chinese biotech firm secures Pfizer deal despite trade tensions

Pfizer will produce the drug, which targets lung and colorectal cancers, in the US and take a US$100 million stake in China’s 3SBio.

videocam
3SBio was established in 1993 with an initial focus on interferons, a type of protein that helps the immune system. Photo: Handout
Biomedicine: Companies

Hong Kong’s Phase Scientific gets US$34 million to advance test for HPV

Company says its test is the world’s first urine-based screening for the virus that causes 95 per cent of cervical cancer cases.

Biomedicine: Companies

China’s weight-loss drug market to lure entrants as Eli Lilly, Novo dominate

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley says.

videocam
Artificial intelligence

Hong Kong healthcare investor looks for biotech’s ‘DeepSeek moment’ in China

ORI Capital is planning a US$350 million fund to focus on Chinese biotech, with hopes that AI will help beat the market.

ORI Capital founder Simone Song Hong Fang, pictured at her Sun Hung Kai Centre office in Wan Chai on April 17, 2021, sees a big opportunity in biotechnology. Photo: Jonathan Wong
United States

Opinion | Trump’s attack on science risks dismantling a century of innovation

Restrictive visa policies, rhetoric targeting academic institutions and proposed budget cuts to scientific agencies mark the start of US retreat.

videocam
Illustration: Craig Stephens
Science

Drug trial offers hope for patients with hard-to-treat lung cancer in China, US

New medication appears to be safer and more effective than standard therapy, according to trial led by Chinese and US scientists.

videocam
7
Biomedicine: Companies

Pharus, an AI-powered cancer test developer, taps Hong Kong funds

Pharus Diagnostics, backed by Li Ka-shing, seeks Hong Kong funds for AI-driven cancer tests.

Quantum computing

Chinese quantum computing firm tackles breast cancer screenings, drug design

Hefei-based Origin Quantum has demonstrated its computer’s ability to process medical imaging data ‘exponentially faster’ than classical machines.

Scientists work on the Origin Wukong superconducting quantum computer. Photo: Origin Quantum
China property

Beijing, Shanghai lead global construction of life sciences centres, CBRE says

Construction of nearly 14 million sq ft of R&D facilities is under way in China’s top two cities, report says.

The Zhongguancun life science park in Beijing. China leads the world in the construction of life science facilities, according to CBRE. Photo: Handout
Science

Beijing almost ready to switch on world’s most powerful X-ray light source

As construction finishes on China’s High Energy Photon Source, scientists are lining up to use it to further their research.

videocam
10
Hong Kong

This week in PostMag: from André Fu’s designs to stem cell therapy

Stunt double Jason Li talks about his journey from squash courts to the set of Transformers while we look at Fu’s Dusit Thani Bangkok project.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement